The Food and Drug Administration (FDA) has approved Restylane® Defyne (Galderma) for the augmentation and correction of mild to moderate chin retrusion for adults over the age of 21 years.

Restylane Defyne is a sterile, clear, homogeneous soft hyaluronic acid gel containing 3mg/mL of lidocaine hydrochloride. The approval was based on data from a randomized, no-treatment controlled, evaluator-blinded phase 3 trial that evaluated the efficacy and safety of Restylane Defyne in adults 22 years of age and older for chin augmentation and correction of chin retrusion.

Results showed that 74% of Restylane Defyne-treated patients achieved significantly improved chin projection for up to 1 year as measured by the Galderma Chin Retrusion Scale (GCRS); 86% of patients achieved GCRS improvement as early as 12 weeks. 

Additionally, the trial met key secondary end points including positive aesthetic outcomes in FACE-Q and Global Aesthetic Improvement Scale (GAIS) questionnaires. At 12 weeks, 99% of patients reported improvement in the appearance of their chin projection, and 96% of injectors reported improvement in the appearance of the patients’ chin projection up to 1 year.

Continue Reading

Restylane Defyne is also indicated for the correction of moderate to severe, deep facial wrinkles and folds in patients over the age of 21. Restylane Defyne is part of a family of aesthetic medicine products that include Restylane, Restylane-L, Restylane Lyft with Lidocaine, Restylane Silk, Restylane Refyne, and Restylane Kysse.


Galderma receives FDA approval for Restylane® Defyne for chin augmentation. [press release]. Fort Worth, TX: Galderma; February 1, 2021.